SCHEMBL207265

SCHEMBL207265

Brc1ccc2o[c]nc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.37
BACE1 P56817 1/20 0.35
HTT P42858 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
PABPC1 P11940 1/20 0.33
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207175 0.83 BACE1 (0.34) AHRBACE1HTTCYP1A2CYP2C19
SCHEMBL4152683 0.75 RAB9A (0.42) HTTCYP1A2CYP2C19MEN1KMT2A
SCHEMBL207390 0.75 LMNA (0.44) AHRHTTCYP1A2CYP2C19MEN1
SCHEMBL938963 0.75 NPC1 (0.42) CYP1A2NPC1ALDH1A1TP53MAPT
SCHEMBL940594 0.72 ALDH1A1 (0.44) HTTMEN1KMT2ANPC1ALDH1A1
SCHEMBL11784689 0.71 RAB9A (0.42) HTTCYP1A2MEN1KMT2ANPC1
SCHEMBL407727 0.71 PKM (0.45) BACE1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL6411255 0.71 NPC1 (0.36) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL5708068 0.69 NPC1 (0.35) CYP1A2CYP2C19MEN1KMT2ANPC1
SCHEMBL7278572 0.68 HTR1A (0.41) KMT2AALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US claimed
WO-2021216812-A1 GALACTOKINASE INHIBITORS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-10-28 WO claimed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 US claimed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 EP claimed
US-10471061-B2 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-11-12 US claimed
WO-2019032743-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-02-14 WO claimed
US-20190030031-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE US OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) 2019-01-31 US claimed
EP-2389066-B1 CYCLOPENTADIONE DERIVED HERBICIDES SYNGENTA LTD (GB) 2017-07-05 EP claimed
US-20170035760-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2017-02-09 US claimed
EP-2387569-B1 HERBCIDES SYNGENTA LTD (GB) 2016-06-15 EP claimed
US-8895474-B2 Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds SYNGENTA LIMITED (GB) 2014-11-25 US claimed
US-8865623-B2 Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds SYNGENTA LIMITED (GB) 2014-10-21 US claimed
US-20140288100-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-09-25 US claimed
WO-2013043192-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-03-28 WO claimed
US-4996204-A Antidiabetic agents PFIZER INC. (US) 1991-02-26 US claimed
CN-118239937-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 CN disclosed
CN-118239938-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 CN disclosed
US-5385925-A Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them DR. KARL THOMAE GMBH (DE) 1995-01-31 US disclosed
EP-0582643-A1 PYRIDAZINONE ACETIC ACIDS PFIZER INC. (US) 1994-02-16 EP disclosed
EP-0468470-A1 Benzimidazoles, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1992-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190030031-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, GCK AHR 4171/4885BACE1 1420/4885HTT 1911/4885
US-20140288100-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, B4GALT1 AHR 4271/4885BACE1 1326/4885HTT 1996/4885
US-20170035760-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, B4GALT1 AHR 4203/4885BACE1 1339/4885HTT 2006/4885
US-20230158025-A1 GALACTOKINASE INHIBITORS GALK1, GCK, GCKR AHR 3495/4885BACE1 1149/4885HTT 3466/4885
US-10471061-B2 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders GALK1, GALC, GCK AHR 4171/4885BACE1 1420/4885HTT 1911/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E AHR 4820/4885BACE1 3801/4885HTT 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.